Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A trial assessing Coronavirus vaccine

Next Previous
Trial Profile

A trial assessing Coronavirus vaccine

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 18 Jan 2021

Print Profile Download Citation

At a glance

  • Drugs GEO CM1 (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 11 Jan 2021 According to a Geovax media release, National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the Company a Small Business Innovative Research (SBIR) grant in support of its development of a vaccine against SARS-CoV-2, the virus that causes COVID-19
    • 20 Mar 2020 New trial record
    • 18 Mar 2020 According to a Geovax media release, this trial is expected to start before the end of this year.

Trial Overview

Purpose

This trial will be assessing the coronavirus vaccine.

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections treatment -

Subjects

  • Subject Type patients
  • Sex male & female
  • Age Group adult

Trial Details

Organisations

  • Affiliations GeoVax Labs

Trial Dates

Other Details

  • Design prospective
  • Phase of Trial Phase I
  • Location Unknown
  • Focus Therapeutic Use

Interventions

Drugs Route Formulation
GEO CM1Primary Drug
-
-

Coronavirus-vaccine

Trial History

Event Date Event Type Comment
11 Jan 2021 Other trial event According to a Geovax media release, National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the Company a Small Business Innovative Research (SBIR) grant in support of its development of a vaccine against SARS-CoV-2, the virus that causes COVID-19 Updated 18 Jan 2021
20 Mar 2020 New trial record New trial record Updated 20 Mar 2020
18 Mar 2020 Other trial event According to a Geovax media release, this trial is expected to start before the end of this year. Updated 20 Mar 2020

References

  1. GeoVax Labs. GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program. Media-Rel 2020;.

    Media Release

  2. GeoVax Labs. GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development. Media-Rel 2021;.

    Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG
Legal
Back to top